Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

By L. Kyne, M. Warny, A. Qamar, C. Kelly. New England Journal of Medicine, 2000

996 citations recorded by the source corpus.

Subfields: Gastroenterology, Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/dc5024935f2fab7c49d1f1105ae8da4e49075c73

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. J. Bartlett

In Infectious Diseases

1. J. Bartlett
2. Louis Valiquette
3. J. Pépin
4. D. Menzies

In Surgery

1. J. Bartlett
2. D. Menzies

Citations in the corpus

• Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications (2002, background): “Increased use of antibiotics, a concomitant suppression of antiinflammatory cytokines, and inability to mount an antibody-mediated response to toxins may all play some role.(11,17) The lung transplant population appears especially susceptible to C.”
• Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies (2004, background): “1 billion in the United States each year.(4) The main cause of this problem is believed to be antibiotic disruption of the normal intestinal flora, resulting in overgrowth of C.”
• Narrative Review: The New Epidemic of Clostridium difficileAssociated Enteric Disease (2006, methodology): “Several methods are used to treat relapsing disease, including biotherapy or probiotics (such as Saccharomyces boulardii and Lactobacillus rhamnosus GG) (58–61), stool implants (62), immunotherapy (intravenous immunoglobulin) (48, 49), and tapering or pulse dosing of oral vancomycin (54, 61).”
• Recommendations for Surveillance of Clostridium difficile–Associated Disease (2007, background): “difficile toxins A and B.(35,36) However, protection is also observed in humans and ani­ mal models when colonization occurs with nontoxigenic strains.”
• Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. (2005, background): “difficile toxin A and age of 165 years were associated with recurrences; baseline and day 12 anti–toxin A IgG concentrations did not differ on the basis of age, but power was limited in these studies [22, 23].”
• Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity (2004, background): “difficile infection.(3,14,15) Second, decades of insufficient capital investment in Quebec hospitals have resulted in conditions of hygiene that facilitate the transmission of pathogens such as C.”
• Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. (2005, background): “Prior studies that identified comorbidities as a risk factor for CDAD did not adjust for both age and duration of hospital stay [10, 12, 15, 21].”